<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648736</url>
  </required_header>
  <id_info>
    <org_study_id>17-164</org_study_id>
    <nct_id>NCT03648736</nct_id>
  </id_info>
  <brief_title>Time Course of Circulating Myocardial Biomarkers After a TASH Procedure.</brief_title>
  <acronym>TASH</acronym>
  <official_title>Time Course of Circulating Myocardial Biomarkers After a TASH Procedure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the released myocardial substances in blood of HOCM patients after TASH
      procedure (small &quot;controlled&quot; myocardial infarction). This helps to identify new
      pathomechanisms and biomarker and thus provides a better understanding of development and
      progress of cardiac insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients who receive a TASH procedure in the Medical Clinic I routinely receive routinely
      implementation of arterial pressure catheter for invasive blood pressure monitoring (usually
      Arteria radialis) as well as a central venous catheter. Directly after the procedure, the
      blood is taken through the central venous catheter. The operation is then terminated as
      planned.

      The postoperative treatment is performed according to the Standard Operating Procedures
      (SOPs) of the Medical clinic I -regular blood sampling is performed to monitor the patient's
      cardiac, renal and hepatic lab values. The patient is released on the 3-5th post-operative
      day.

      As part of a routine outpatient visit to the Medical Clinic I 1 week and 1 month after the
      TASH procedure, an anamnestic record as well as a blood analysis is made. One month after the
      TASH procedure, an echocardiographic follow-up of the HOCM is routinely performed.

      Adverse events or serious adverse events are documented, assessed and reported in accordance
      with GCP (good clinical practice).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Time course of FGF23 (c-terminal)</measure>
    <time_frame>1 month</time_frame>
    <description>from baseline to 4 weeks after TASH procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of FGF23 (intact)</measure>
    <time_frame>1 month</time_frame>
    <description>from baseline to 4 weeks after TASH procedure</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiac Insufficiency</condition>
  <arm_group>
    <arm_group_label>HOCM patients</arm_group_label>
    <description>selected for routine TASH procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood withdrawal</intervention_name>
    <description>peripheral-venous before TASH, day 1, 2, 3, one week and one month after TASH procedure
central-venous during TASH</description>
    <arm_group_label>HOCM patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HOCM patients selected for routine TASH procedure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a clinical indication for TASH procedure

          -  an access to blood vessels

          -  a person qualified for legal acts, mentally abte to follow the instructions of study
             stuff

        Exclusion Criteria:

          -  patients with severe anaemia - Hb &lt;8 mg/dL

          -  patients with acute infectious diseases (e.g. pneumonia)

          -  patients with acute myocardial ischaemia (e.g. angina pectoris or ECG alterations
             under strain)

          -  patients with acute coronary syndrome in the last three months

          -  patients that were hospitalized for Acute Heart Failure during the last month and had
             to be treated by diuretics or inotropes

          -  a pregnant and/or breastfeeding women

          -  Persons that are located by a court or administrative decision in an Institution

          -  Persons with a relationship of dependency to investigator

          -  Persons with simultaneous participation in another clinical trial

          -  administration of an investigational drug 30 days before start of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Stöhr, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH Aachen University, Aachen University Hospital, Medical Clinic I</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Stöhr, Dr.</last_name>
    <phone>+49 241 80 36351</phone>
    <email>rstoehr@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aachen University Hospital; Medical Clinic I - Cardiology, Pneumology, Angiology and Internal Intensive Medicine</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Stöhr, Dr. med.</last_name>
      <phone>+49 241 80 36351</phone>
      <email>rstoehr@ukaachen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Jessup M, Brozena S. Heart failure. N Engl J Med. 2003 May 15;348(20):2007-18. Review.</citation>
    <PMID>12748317</PMID>
  </reference>
  <reference>
    <citation>Jessup M, Brozena SC. Epilogue: support devices for end stage heart failure. Cardiol Clin. 2003 Feb;21(1):135-9. Review.</citation>
    <PMID>12790052</PMID>
  </reference>
  <reference>
    <citation>Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 Jan;8(1):30-41. doi: 10.1038/nrcardio.2010.165. Epub 2010 Nov 9. Review.</citation>
    <PMID>21060326</PMID>
  </reference>
  <reference>
    <citation>Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am. 2004 Sep;88(5):1145-72. Review.</citation>
    <PMID>15331311</PMID>
  </reference>
  <results_reference>
    <citation>Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011 Nov;121(11):4393-408. doi: 10.1172/JCI46122. Epub 2011 Oct 10.</citation>
    <PMID>21985788</PMID>
  </results_reference>
  <results_reference>
    <citation>Leifheit-Nestler M, Große Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, Klintschar M, Becker JU, Erbersdobler A, Aufricht C, Seeman T, Fischer DC, Faul C, Haffner D. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016 Jul;31(7):1088-99. doi: 10.1093/ndt/gfv421. Epub 2015 Dec 17.</citation>
    <PMID>26681731</PMID>
  </results_reference>
  <results_reference>
    <citation>Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009 Dec;207(2):546-51. doi: 10.1016/j.atherosclerosis.2009.05.013. Epub 2009 May 21.</citation>
    <PMID>19524924</PMID>
  </results_reference>
  <results_reference>
    <citation>Andrukhova O, Slavic S, Odörfer KI, Erben RG. Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23. J Bone Miner Res. 2015 Oct;30(10):1831-9. doi: 10.1002/jbmr.2527. Epub 2015 May 6.</citation>
    <PMID>25858796</PMID>
  </results_reference>
  <results_reference>
    <citation>Andersen IA, Huntley BK, Sandberg SS, Heublein DM, Burnett JC Jr. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant. 2016 May;31(5):767-72. doi: 10.1093/ndt/gfv398. Epub 2015 Dec 13.</citation>
    <PMID>26666498</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGF23, TASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The results of the study will be published in a scientific paper. The Ethics Committee will be informed about the results of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

